(Total Views: 184)
Posted On: 12/22/2022 11:05:45 AM
Post# of 101
$RIGL News Article - Rigel Announces Availability of REZLIDHIA(TM) (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation https://marketwirenews.com/news-releases/rige...65847.html
(0)
(0)
My Twitter: WhyteStocks
Scroll down for more posts ▼
